

Specific effects of ecstasy and other illicit drugs on cognition in poly-substance users

T. Schilt^{1,2*}, M. M. L. de Win³, G. Jager⁴, M. W. Koeter^{1,2}, N. F. Ramsey⁴, B. Schmand^{5,6}
and W. van den Brink^{1,2}

¹ Department of Psychiatry, Academic Medical Center, University of Amsterdam, The Netherlands

² Amsterdam Institute for Addiction Research, The Netherlands

³ Department of Radiology, Academic Medical Center, University of Amsterdam, The Netherlands

⁴ Department of Neurosurgery, University Medical Center Utrecht, The Netherlands

⁵ Department of Neurology, Academic Medical Center, University of Amsterdam, The Netherlands

⁶ Department of Psychology, University of Amsterdam, The Netherlands

Background. A large number of studies, reviews and meta-analyses have reported cognitive deficits in ecstasy users. However most ecstasy users are polydrug users, and therefore it cannot be excluded that these deficits are (partly) the result of drugs other than ecstasy. The current study, part of the Netherlands XTC Toxicity (NeXT) study, investigates the specific sustained effects of ecstasy relative to amphetamine, cocaine and cannabis on the brain using neuropsychological examination.

Method. A stratified sample of 67 subjects with such a variation in type and amount of drug use was included that correlations between the consumption of the various drugs were relatively low allowing stepwise linear multiple regression analyses to differentiate between the effects of ecstasy and those of other substances. Subjects were assessed with neuropsychological tests measuring attention, working memory, verbal and visuospatial memory, and visuospatial ability.

Results. Ecstasy use [mean 327 (s.d. = 364) tablets in lifetime] had a specific significant dose-related negative effect on verbal delayed recall after adjusting for the use of other drugs.

Conclusions. These findings strongly suggest a specific sustained negative effect of ecstasy use on verbal memory. The clinical relevance is not immediately clear, because test performance generally remained within the normal range. However the magnitude of the effect is substantial ($d > 0.5$) and long-term consequences cannot be excluded.

Received 28 November 2006; Revised 5 September 2007; Accepted 9 October 2007

Key words: cannabis, cognition, ecstasy, MDMA, memory, neuropsychology, neurotoxicity, polydrug use.

Introduction

The popularity of ecstasy (3,4-methylenedioxymethamphetamine; MDMA) seems to be slightly decreasing in both Western Europe and the USA (Compton *et al.* 2005; Huisman, 2005; Nabben *et al.* 2005), but ecstasy is still an extensively used recreational drug. Serious neurotoxic effects of ecstasy on the serotonin system have been shown in animals (Ricaurte *et al.* 2000) and these effects were repeatedly confirmed in humans (Reneman *et al.* 2006). Since serotonin is involved in cognitive processes (Meneses, 1999), it is not surprising that many studies also revealed neuropsychological deficits in ecstasy users

(Gouzoulis-Mayfrank & Daumann, 2006a). The most consistent finding is a negative effect of ecstasy use on verbal memory. Also deficits in executive functions, visuospatial memory and visuospatial ability have been reported, but these findings are less consistent.

A problem in investigating the potential neurotoxic effects of ecstasy is that most ecstasy users are polydrug users (Fox *et al.* 2001; Gouzoulis-Mayfrank & Daumann, 2006b). Besides cannabis, also amphetamine and cocaine are commonly used by people using ecstasy (Pedersen & Skrandal, 1999; van Ours, 2005), leaving open the question whether the observed cognitive deficits are attributable to the use of ecstasy, to other drugs, or to a combination of ecstasy and other drugs. Indeed, several studies have reported negative effects of cocaine or amphetamine on executive functioning, attention and memory (McKetin & Mattick, 1998; Bolla *et al.* 1999). It has also been argued that neuropsychological deficits in ecstasy users

* Address for correspondence: T. Schilt, M.Sc., Department of Psychiatry, PBO 429, Academic Medical Center – University of Amsterdam, PO Box 75867, 1070 AW Amsterdam, The Netherlands.
(Email: t.schilt@amc.uva.nl)

are caused by cannabis rather than by ecstasy (Montgomery *et al.* 2005a). For example, two studies failed to find significant differences on cognitive tests between combined ecstasy–cannabis users and users of cannabis only, and both groups performed worse on verbal memory tests than non-using controls (Croft *et al.* 2001; Dafters *et al.* 2004). However, it has also been suggested that cannabis attenuates the effect of ecstasy (Parrott *et al.* 2004).

Although some studies tried to control for polydrug use (Fox *et al.* 2001; Medina *et al.* 2005), the question is still not settled because high correlations between the drug-use variables and the related problems of multicollinearity in the statistical analyses resulted in findings that were difficult to interpret (Montgomery *et al.* 2005a, b).

Therefore, the present study investigated the sustained effects (after at least 2 weeks of abstinence) of ecstasy use on cognition in a study population with such a variation in type and amount of drug use that correlations between the use of ecstasy and other substances were relatively low allowing a valid interpretation of the results of multiple linear regression models. Consistent with the literature, we hypothesized that high-dose ecstasy use has a significant negative effect on verbal memory, independent of the effects of the use of other substances. In addition, no clear hypotheses can be formulated about the effects of ecstasy on attention, working memory, visuospatial memory and visuospatial performance.

Method

The present study is part of the Netherlands XTC Toxicity (NeXT) study, a larger study investigating causality, course and clinical relevance of ecstasy neurotoxicity. A detailed description of the NeXT study can be found in a special design paper (de Win *et al.* 2005).

Participants and design

Between October 2002 and January 2005, 71 subjects (aged 18–35 years) were included. Recruitment took place by means of a combination of targeted site sampling at locations such as dance events, discotheques, youth fairs, universities, colleges and parks, advertisements on dance and drug-related Internet sites and in newspapers, and snowball sampling. We composed a single sample of subjects with varying histories of drug use, keeping correlations between the substances as low as possible, in order to be able to distinguish the effect of ecstasy from the effects of other drugs. Exclusion criteria were: a major systemic, neurological or

neuropsychiatric disorder, the use of psychotropic medications that may influence cognitive functioning such as serotonin (5-HT) reuptake inhibitors, pregnancy, and the use of intravenous drugs. Subjects had to abstain from the use of psychoactive drugs for at least 2 weeks prior to examinations and from alcohol for at least 1 week prior to examinations. Drug use during the days before assessment was checked through urinalysis (enzyme-multiplied immunoassay for amphetamines, MDMA, opiates, benzoylecgonine, benzodiazepines, 11-nor- Δ^9 -THCCOOH, ethanol). Previous ecstasy use was checked through hair analysis (gas chromatography/mass spectroscopy).

After inclusion, all subjects underwent neuropsychological assessment. The examiner was blind to the type and amount of substance use of the subject. Lifetime use of ecstasy (number of tablets), cannabis (number of joints), amphetamines (number of occasions), cocaine (number of occasions), and use of alcohol (units/week) and tobacco (cigarettes/week) were assessed with substance-use questionnaires and the substance abuse scales of the Mini International Neuropsychiatric Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV clinical disorders (Sheehan *et al.* 1998). An estimate of verbal intelligence was made using the Dutch version of the National Adult Reading Test (Nelson & O'Connell, 1978), the Dutch Adult Reading Test (DART), as it is relatively insensitive to cognitive impairments caused by neurological disorders (Schmand *et al.* 1991).

Subjects were paid for their participation (€100 or €150 per session depending on number of assessments). The study was approved by the local medical ethics committee. After complete description of the study, each subject gave written informed consent. Besides neuropsychological testing, the subjects underwent brain imaging; results of these studies will be described elsewhere.

Assessments

Attention, working memory and executive functioning

Paced Auditory Serial Addition Test (Gronwall, 1977). Subjects have to add numbers to a preceding number presented by a recorded male voice to a preceding number. Numbers are presented in two trials at a speed of 2.4 s and 1.6 s per digit respectively. The outcome parameter is the total number of correct calculations per trial (maximum 60 points each).

Digit span (Wechsler, 1981; Lindeboom & Matto, 1994). Subjects have to repeat a series of digits read aloud by the examiner, first in forward order, than

Table 1. Demographics and classification of drug use ($n=67$)

	Subjects (n)	Mean (S.D.)	Median	Range
Males/females	40/27			
Age	67	23.5 (3.9)	22.8	18.6–37.8
IQ (DART score)	67	101.3 (7.7)	100.0	83–122
Level of education ^a				
Junior general secondary or vocation education	11			
Senior general secondary or vocation colleges	52			
Universities	4			
Drug use				
Ecstasy, >10 tablets in lifetime	31/67	327 (364)	250	15–2000
Amphetamine, >10 occasions in lifetime	17/67	145 (157)	120	15–600
Cocaine, >10 occasions in lifetime	21/67	75 (71)	50	12–300
Cannabis, >50 joints in lifetime	38/67	1300 (1690)	688	56–6650
Alcohol, >10 units per week	33/67	23 (12)	18	12–60
Tobacco, >10 cigarettes per week	30/67	82 (42)	80	17–160

S.D., Standard deviation; IQ, intelligence quotient; DART, Dutch Adult Reading Test.

^a Junior, approximately 12 years of full-time education; senior, approximately 12–16 years of full-time education; university, approximately 20 years of full-time education (Central Bureau of Statistics, The Netherlands).

in backward order. The outcome parameter is the number of correctly reproduced series of digits per order (maximum 21 each).

Verbal memory

A Dutch version of the Rey Auditory Verbal Learning Test (RAVLT) (Rey, 1964; Van der Elst *et al.* 2005). Subjects have to memorize a series of 15 nouns in five learning trials. Immediate recall is tested after each trial. The outcome parameter is the sum of correctly reproduced words over five trials (maximum 75). Delayed recall and recognition are measured after 20 min. Outcome parameters are total number of correctly reproduced words (maximum 15) and the total number of incorrect words that are mentioned by the subject during the learning trials and the delayed recall trial (confabulations).

Visual memory

The Memory for Designs test (Graham & Kendall, 1960). The original test with 14 geometrical figures was split into two separate tests to obtain two parallel versions. Also the mode of administration was adapted to mimic the RAVLT. After presentation of seven figures during 5 s each, subjects have to draw the figures from memory. This is repeated five times. The outcome parameter is the number of correctly reproduced elements in five learning trials (maximum 105). Delayed reproduction is measured after 15 min; the outcome parameter is the number of correctly reproduced elements (maximum 21).

Visuospatial functioning

The Mental Rotation Task (MRT) (Shepard & Metzler, 1971). Participants are presented with 20 pairs of block designs drawn from different points of view. They have to judge whether pairs of designs are identical or different. The outcome parameter is the total number of correct answers in 6 min (maximum 40).

A computerized and adapted version of the Judgment of Line Orientation (JoLO) (Benton *et al.* 1978). The JoLO requires subjects to identify which two of 11 lines presented in a semicircular array have the same orientation in a two-dimensional space as two target lines. The original JoLO was made more difficult to reduce its ceiling effect and to increase its sensitivity to brain dysfunction. The target lines in our assessments were only shown for 1 s, directly followed by the 11 lines. The outcome parameter is the number of correctly judged pairs of lines (maximum 30).

Statistical analyses

Drug-use variables were right-skewed, even after log-transformation. Also, self-report histories of drug use may be inaccurate and the amount of MDMA in ecstasy tablets varies. Therefore, substance variables were dichotomized using a cut-off score to maximize contrast between users and non-users of a particular drug. Table 1 shows cut-off values, frequency distributions, mean values and S.D. and median scores for the substance variables. The associations between the dichotomized substance-use variables were expressed

Table 2. Association between the categorical drug variables ($n=67$)^a

	Ecstasy	Amphetamine	Cocaine	Cannabis	Alcohol	Tobacco
Ecstasy		0.49	0.54	N.S.	N.S.	0.43
Amphetamine			0.49	N.S.	N.S.	N.S.
Cocaine				N.S.	N.S.	0.30
Cannabis					0.38	0.42
Alcohol						N.S.
Tobacco						

N.S., Non-significant.

^a Correlations (Phi, Pearson χ^2 , $p < 0.05$, two-tailed) between the dichotomized drug-use variables.

as Phi statistics, and significance was tested using a χ^2 test.

The effect of ecstasy on the outcome parameters was estimated with two different stepwise linear regression models. Model 1 concerned the upper bound estimate for the effect of ecstasy on cognition. In this model, the covariates gender, intelligence quotient (IQ) and age were entered in the first step, followed by ecstasy in the second step. The added effect of ecstasy was quantified as the R^2 change between the first and the second step. It should be noted, however, that the effect of ecstasy in the second step is likely to be an overestimation of the real independent effect of ecstasy on the neuropsychological outcome, due to a lack of correction for the potential effect of other drugs that were used. To assess whether ecstasy use had an effect on cognition independently of the effects of all other drugs, we used a second regression model (model 2) in which the first step involved the entering of all dichotomous substance-use variables other than ecstasy use, together with gender, IQ and age as covariates. In the second step ecstasy use was added to the model. Model 2 gives a lower bound estimate for the effect of ecstasy on cognition, adjusted for the effect of all other substances, gender, IQ and age. This second model probably results in an underestimation of the real independent effect of ecstasy, due to an overcorrection for the potential effects of other drugs correlated with the use of ecstasy. Potential collinearity problems were tested using the tolerance factor (TF) and the variance inflation factor (VIF).

To explore the dose-response relationship, correlation analyses were performed within the group of ecstasy users, with total amount of ecstasy use (log-transformed) and cognitive test parameters as variables, followed by partial correlations taking other substances, gender, IQ and age into account as potential confounders. In the same way the correlation between cognitive test parameters and time since

last ecstasy tablet and duration of ecstasy use was analysed.

Analyses were performed using SPSS version 12.0.1 (SPSS Inc., Chicago, IL, USA). P values < 0.05 were considered statistically significant. Mean values reported in the results and discussion sections are followed by their standard deviations.

Results

Sample characteristics and substance use

Two subjects were excluded because of dyslexia and attention deficit disorder; two subjects were excluded because they used ecstasy less than 2 weeks before assessment, leaving 67 subjects for analyses. Sociodemographic data of the total sample and patterns of drug use, including cut-off values for classification as 'user' of a specific drug, are presented in Table 1. No significant differences in age, gender and IQ were found between ecstasy users and non-ecstasy users (data not shown). Hair analysis confirmed past ecstasy use in 85% of the subjects. In almost all subjects that reported to be ecstasy-naïve, results from hair analysis were congruent (96%). Last use of ecstasy was on average 8.7 (S.D.=9.9, range 2–46) weeks before examination. Duration of ecstasy use was on average 73.7 (S.D.=38.0, range 16–158) months. Although we aimed to keep the associations between the substances as low as possible, still some significant associations between the use of different substances were present (Table 2). However, because all associations were less than 0.55, multicollinearity was not a problem (TF 0.55–0.86, VIF 1.2–1.8), and it was decided that all substances could be entered separately into the different regression models. There were no significant correlations between substance use and demographic variables, except that there were more cigarette smokers in lower educated subjects (data not shown).

Table 3. Cognitive performance (raw scores)

	Ecstasy users, <i>n</i> = 31, > 10 tablets in lifetime, median 250 tablets	Non-ecstasy users, <i>n</i> = 36, ≤ 10 tablets in lifetime, median 0 tablets
RAVLT immediate recall (maximum 75 words)	55.2 (6.5)	59.7 (5.6)
RAVLT delayed recall (maximum 15 words)	12.0 (2.5)	13.8 (1.3)
RAVLT confabulations (words)	3.8 (3.3)	1.6 (1.8)
Memory for Designs immediate (maximum 105 elements)	89.0 (9.2)	94.1 (6.3)
Memory for Designs delayed (maximum 21 elements)	20.7 (0.8)	20.8 (0.6)
Digit span forward (maximum 21 series)	14.5 (2.1)	15.0 (2.9)
Digit span backward (maximum 21 series)	10.7 (2.0)	11.5 (2.4)
PASAT 2.4 (maximum 60 hits)	49.8 (6.1)	51.0 (8.3)
PASAT 1.6 (maximum 60 hits)	40.4 (7.5)	41.8 (8.2)
Judgement of Line Orientation (maximum 30 pairs)	22.5 (4.1)	22.1 (3.8)
Mental Rotation Test (maximum 40 hits)	22.0 (7.8)	24.6 (7.2)

RAVLT, Rey Auditory Verbal Learning Test; PASAT, Paced Auditory Serial Addition Test.
Values are means (standard deviations).

Neuropsychological testing

Ecstasy and cognition

Table 3 shows the raw scores on all cognitive tests for ecstasy users and non-ecstasy users. Linear multiple regression analyses with neuropsychological test parameters as dependent variables showed that ecstasy use, adjusted for gender, age and IQ (model 1), was significantly associated with RAVLT immediate recall, delayed recall, confabulations, and Memory for Designs immediate reproduction. After adjusting for other substances (model 2), ecstasy use was still significantly associated with RAVLT delayed recall and confabulations, but not for RAVLT immediate recall and Memory for Designs immediate reproduction (Table 4). The ecstasy-related variance in RAVLT delayed recall, adjusted for gender, age and IQ (model 1), amounted to a maximum of 16.1% ($F_{\text{change}}=13.3$, $df=1$, 62, $p=0.001$) of the total variance (upper bound); adjusted for other substances (model 2), ecstasy use accounted for at least 6.4% ($F_{\text{change}}=5.8$, $df=1$, 57, $p=0.02$) of the total variance (lower bound). For RAVLT confabulations this was 17.3% ($F_{\text{change}}=13.9$, $df=1$, 62, $p<0.001$) and 11.0% ($F_{\text{change}}=8.8$, $df=1$, 57, $p=0.004$), respectively. The effect of ecstasy use on the other neuropsychological tests was not significant (see Table 4). Gender had no significant modifier effect on the results.

Correlation analysis within the group of ecstasy users showed a significant negative correlation between amount of lifetime ecstasy use (log-transformed) and RAVLT delayed recall ($r=-0.37$, $p=0.02$, one-tailed). This association remained

significant after adjusting for other substances, gender, age and IQ ($r=-0.40$, $p=0.03$, one-tailed). No significant correlation was found between the amount of ecstasy use and RAVLT confabulations. Also no significant correlations between abstinence period of ecstasy or duration of ecstasy use with RAVLT delayed recall or confabulations were found.

Other substances and cognition

Amphetamine use had a significant negative effect on Memory for Designs immediate reproduction and the MRT. Cannabis use showed a significant positive effect on RAVLT delayed recall, Digit Span forward and JoLO (more cannabis use led to better results). When all combined cannabis-ecstasy users were excluded from the analysis, the positive effect of cannabis use on RAVLT delayed recall was not significant anymore [β decreased from 0.33 ($p=0.02$) to 0.24 ($p=0.14$)]. Alcohol use showed a significant negative effect on RAVLT delayed recall. No significant effects of cocaine and nicotine on the cognitive test parameters were observed.

Discussion

The objective of this study was to assess the sustained specific effects of ecstasy use on cognition independent of the use of other substances. Multiple regression analyses revealed that ecstasy independently accounted for a significant part of the variance in verbal memory test outcome: after correction for the potential effect of the use of other substances, ecstasy was still significantly and dose-related associated with

Table 4. Relationship between different drug use and neuropsychological performance ($n = 67$)

	R ² change with ecstasy		Model 2: Predictor variables (standardized β coefficients, shown if > 0.10)								
	Model 1, upper bound ^a	Model 2, lower bound ^b	Ecstasy	Amphetamine	Cocaine	Cannabis	Alcohol	Nicotine	Gender	IQ	Age
RAVLT immediate	0.105**	0.019	−0.184	−0.275	−0.228	0.174	–	0.116	0.280*	–	–
RAVLT delayed	0.161***	0.064*	−0.341*	−0.236	−0.109	0.329*	−0.239*	–	0.216	−0.159	–
RAVLT confabulations	0.173***	0.110**	0.448**	−0.157	0.141	−0.104	0.205	–	−0.220	–	–
Memory for Designs immediate	0.096**	0.006	−0.103	−0.368*	−0.108	0.171	–	–	−0.114	–	0.241*
Memory for Designs delayed	0.003	0.007	0.117	−0.196	–	−0.181	0.125	−0.101	−0.152	0.227	0.185
Digit span forward	0.000	0.012	−0.150	–	0.262	0.316*	–	–	–	0.303*	–
Digit span backward	0.013	0.001	–	−0.170	–	0.202	0.190	–	–	0.286*	–
PASAT 2.4	0.000	0.014	0.161	−0.178	−0.110	0.151	–	−0.161	−0.112	0.168	–
PASAT 1.6	0.003	0.001	–	–	−0.195	–	–	–	–	0.182	0.106
Judgement of Line Orientation	0.002	0.003	–	−0.280	–	0.438**	−0.254	−0.125	−0.129	–	–
Mental Rotation Test	0.013	0.003	–	−0.260*	0.162	–	–	–	−0.570***	0.187	–

IQ, Intelligence quotient; RAVLT, Rey Auditory Verbal Learning Test; PASAT, Paced Auditory Serial Addition Test; DART, Dutch Adult Reading Test.

^a Model 1 (upper bound): R² Change with ecstasy as predictor, corrected for age, gender, DART-IQ.

^b Model 2 (lower bound): R² Change with ecstasy, corrected for other substances, age, gender, DART-IQ.

* $p < 0.05$, ** $p < 0.01$, *** $p \leq 0.001$.

verbal memory impairments, i.e. ecstasy users recalled fewer words and made more confabulation errors than non-users.

Both dose-related subjective experiences of memory impairment reported by ecstasy users (Parrott *et al.* 2002; Rodgers *et al.* 2003) and dose-related objective neuropsychological indicators of decreased verbal memory (Fox *et al.* 2001; Gouzoulis-Mayfrank & Daumann, 2006a) have repeatedly been reported in the literature. However, because most of the earlier investigations suffered from methodological problems due to inadequate control for polydrug use, until now the independent contribution of ecstasy to the decrease of cognitive performance remained unclear. A higher rate of confabulation errors in long-term ecstasy users compared with polydrug controls was also observed in one previous study (Fox *et al.* 2001). Confabulation errors could be due to an incapacity to correctly evaluate the retrieved information and might imply a failure of memory control processes (Burgess & Shallice, 1996; Fox *et al.* 2001) or a failure in strategic retrieval (Moscovitch & Melo, 1997). Another explanation could be that confabulation errors are a consequence of impaired executive functioning, for example a lack of response inhibition. Unfortunately, the literature on executive problems in ecstasy users is inconclusive, reporting executive function deficits in some studies but not in others (Gouzoulis-Mayfrank & Daumann, 2006a).

In the present study, cannabis users who were also using ecstasy showed a significant sustained positive effect on verbal memory. However, this effect was not present in ecstasy-naïve cannabis users. This finding is at odds with two other studies in ecstasy users, in which a negative effect of cannabis use was observed on memory and learning, suggesting that deficits found in ecstasy users were actually related to cannabis use (Croft *et al.* 2001; Dafters *et al.* 2004). However, in both studies the period of abstinence for cannabis was only 48 h, and therefore acute pharmacological effects (intoxication) could not be fully excluded, while this effect was excluded in the current study with a period of abstinence of at least 2 weeks. Since our study demonstrated opposing effects of ecstasy and cannabis on cognition, this may imply that cannabis attenuates the neurotoxic effects of ecstasy. It has been suggested that ecstasy and cannabis may have opposite effects on oxidative stress (Parrott *et al.* 2004). Ecstasy leads to increased oxidative stress, probably resulting in serotonergic neurotoxicity (Green *et al.* 2003), whereas cannabis may act as an antioxidant (Hampson *et al.* 2000) with possibly some neuro-protective effect (Sinor *et al.* 2000). Another hypothesis refers to the different neurotransmitter systems that are affected by ecstasy and cannabis. Cannabis

affects dopamine function whereas MDMA-induced serotonergic toxicity only occurs in the presence of dopaminergic integrity (Sprague *et al.* 1998). Consequently cannabis-induced dopaminergic down-regulation may protect the ecstasy user against serotonergic damage (Croft *et al.* 2001).

In the present study, amphetamine had a negative effect on visual learning and visuospatial functioning. It is therefore possible that the non-verbal memory deficits found in some other studies are (at least partly) caused by concomitant use of amphetamine rather than by ecstasy. In some studies that reported visual memory deficits, it was shown that ecstasy use was accompanied by amphetamine use (Bolla *et al.* 1998; Gouzoulis-Mayfrank *et al.* 2003), and consequently the deficits might not be ascribed to ecstasy alone.

The clinical relevance of the current study is not completely clear. Our data suggest that frequent ecstasy use is responsible for a drop of almost two out of 15 words in a verbal delayed memory task. This is a difference of more than half a standard deviation (Van der Elst *et al.* 2005), which is not only statistically significant but also quite substantial. Nevertheless, this effect is probably too small to be readily noted in daily life of individual subjects, but if the effect is permanent, long-term consequences, like early-onset age-related memory decline, cannot be excluded.

We are well aware of the limitations of this study. Inherent to the cross-sectional design of our study, pre-existent differences cannot be fully excluded. Therefore, no final causal statements can be made. Even so, the current study demonstrates that ecstasy-related associations with delayed memory remain after adequate control for the effect of other substances, and the same is true for the observed dose-response relationship. The dose-response relationship strongly supports the notion that the observed association of ecstasy use and verbal memory is causal. This is also in keeping with our recently reported finding of negative effects on verbal memory after first ecstasy use (Schilt *et al.* 2007). A second limitation is that we had to rely on self-reported drug use in the past. The hair analyses performed in our study do not provide information about frequency or dosage, but the results support the plausibility of the self-reported data in the current study. Furthermore, there was no control on purity of the ecstasy tablets used by the subjects. However, results from pill-testing services in The Netherlands showed that in 95% of the tablets sold as ecstasy, MDMA was the main component (Drugs Informatie en Monitoring System, 2004). Third, we did not investigate environmental circumstances in which the drugs were used, like ambient heat and dehydration, nor did we investigate the simultaneous use

of different drugs at the same time. Interaction effects between those factors and neuropsychological damage have been reported (Topp *et al.* 2004). However, it would be almost impossible to control for all these factors. Fourth, we tried to select the subjects in such a way that correlations between the use of different drugs were as low as possible. However, correlations could not fully be eliminated, which might have weakened the validity of the regression models. Fortunately, specific statistical analyses identified no serious multicollinearity problems. Also, a limitation might be that we were forced to dichotomize the substance-use variables because they were not normally distributed. However, repeating the regression analyses in the whole sample with lifetime substance use as variables (log-transformed) instead of using the dichotomous substance variables did not change the overall results (data not shown). The statistical legitimacy of using regression analysis could be argued, because our sample was relatively small ($n=67$) compared with the number of independent variables ($n=9$), and because a low respondent:variable ratio might result in unstable findings. In order to test the stability of our findings, we conducted a bootstrapping procedure (1000 samples of $n=67$) and a Ridge regression with a biasing constant of 0.05. Both assessments showed that the effect of ecstasy on memory was a stable finding. Finally, this study did not extensively assess executive functions, which hinders the interpretation of the increase of confabulation errors as a consequence of ecstasy use.

In conclusion, our data strongly suggest a specific negative effect of ecstasy use on verbal memory, independent of the use of other drugs. More research on the specific effects of ecstasy or possible interactions between ecstasy and other drugs, and the long-term course of verbal memory functioning in (ex)-ecstasy users is needed.

Acknowledgements

This study was supported by a grant of The Netherlands Organization for Health Research and Development, as part of their Addiction Programme (ZonMw 310-00-036). We thank Dirk Korf for his help on the design of the study, Hylke Vervaeke for subject recruitment and Ivo Bisschops and Sarah Dijkink for their assistance with the logistics and data collection. We also thank Koos Zwinderman for his assistance in analysing the stability of our findings.

Declaration of Interest

None.

References

- Benton AL, Varney NR, Hamsher KD (1978). Visuospatial judgment. A clinical test. *Archives of Neurology* **35**, 364–367.
- Bolla KI, McCann UD, Ricaurte GA (1998). Memory impairment in abstinent MDMA ('ecstasy') users. *Neurology* **51**, 1532–1537.
- Bolla KI, Rothman R, Cadet JL (1999). Dose-related neurobehavioral effects of chronic cocaine use. *Journal of Neuropsychiatry and Clinical Neurosciences* **11**, 361–369.
- Burgess PW, Shallice T (1996). Confabulation and the control of recollection. *Memory* **4**, 359–411.
- Compton WM, Thomas YF, Conway KP, Colliver JD (2005). Developments in the epidemiology of drug use and drug use disorders. *American Journal of Psychiatry* **162**, 1494–1502.
- Croft RJ, Mackay AJ, Mills AT, Gruzeliér JG (2001). The relative contributions of ecstasy and cannabis to cognitive impairment. *Psychopharmacology (Berlin)* **153**, 373–379.
- Dafters RI, Hoshi R, Talbot AC (2004). Contribution of cannabis and MDMA ('ecstasy') to cognitive changes in long-term polydrug users. *Psychopharmacology (Berlin)* **173**, 405–410.
- de Win MM, Jager G, Vervaeke HK, Schilt T, Reneman L, Booij J, Verhulst FC, den Heeten GJ, Ramsey NF, Korf DJ, van den Brink W (2005). The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance. *International Journal of Methods in Psychiatric Research* **14**, 167–185.
- Drugs Informatie en Monitoring System (2004). *Jaarbericht 2004*. DIMS/Trimbos-instituut: Utrecht, The Netherlands.
- Fox HC, Toplis AS, Turner JJ, Parrott AC (2001). Auditory verbal learning in drug-free ecstasy polydrug users. *Human Psychopharmacology* **16**, 613–618.
- Gouzoulis-Mayfrank E, Daumann J (2006a). Neurotoxicity of methylenedioxymphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? *Addiction* **101**, 348–361.
- Gouzoulis-Mayfrank E, Daumann J (2006b). The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. *Journal of Psychopharmacology* **20**, 188–193.
- Gouzoulis-Mayfrank E, Thimm B, Rezk M, Hensen G, Daumann J (2003). Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users. *Progress in Neuro-Psychopharmacological and Biological Psychiatry* **27**, 819–827.
- Graham FK, Kendall BS (1960). Memory-for-design: revised general manual. *Perceptual and Motor Skills* **11**, 147–188.
- Green AR, Mehan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). *Pharmacological Reviews* **55**, 463–508.
- Gronwall DM (1977). Paced auditory serial-addition task: a measure of recovery from concussion. *Perceptual and Motor Skills* **44**, 367–373.
- Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J (2000). Neuroprotective antioxidants from

- marijuana. *Annals of the New York Academy of Science* **899**, 274–282.
- Huisman S** (2005). *Criminaliteitsbeeldanalyse Synthetische Drugs 2002–2004*. Korps Landelijke Politiediensten/Dienst Nationale Recherche (KLPD/NR): Driebergen.
- Lindeboom J, Matto D** (1994). Digit series and Knox cubes as concentration tests for elderly subjects [in Dutch]. *Tijdschrift voor Gerontologie en Geriatrie* **25**, 63–68.
- McKetin R, Mattick RP** (1998). Attention and memory in illicit amphetamine users: comparison with non-drug-using controls. *Drug and Alcohol Dependence* **50**, 181–184.
- Medina KL, Shear PK, Corcoran K** (2005). Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective. *Journal of the International Neuropsychological Society* **11**, 753–765.
- Meneses A** (1999). 5-HT system and cognition. *Neuroscience and Biobehavioral Reviews* **23**, 1111–1125.
- Montgomery C, Fisk JE, Newcombe R** (2005a). The nature of ecstasy-group related deficits in associative learning. *Psychopharmacology (Berlin)* **180**, 141–149.
- Montgomery C, Fisk JE, Newcombe R, Murphy PN** (2005b). The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory. *Psychopharmacology (Berlin)* **182**, 262–276.
- Moscovitch M, Melo B** (1997). Strategic retrieval and the frontal lobes: evidence from confabulation and amnesia. *Neuropsychologia* **35**, 1017–1034.
- Nabben T, Quaak L, Korf DJ** (2005). *NL. Trendwatch. Gebruikersmarkt uitgaansdrugs in Nederland 2004–2005*. Rozenberg Publishers: Amsterdam.
- Nelson HE, O'Connell A** (1978). Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. *Cortex* **14**, 234–244.
- Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J** (2002). Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. *Human Psychopharmacology* **17**, 309–312.
- Parrott AC, Gouzoulis-Meyfrank E, Rodgers J, Solowij N** (2004). Ecstasy/MDMA and cannabis: the complexities of their interactive neuropsychobiological effects. *Journal of Psychopharmacology* **18**, 572–575.
- Pedersen W, Skrandal A** (1999). Ecstasy and new patterns of drug use: a normal population study. *Addiction* **94**, 1695–1706.
- Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ** (2006). Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. *Journal of Psychopharmacology* **20**, 164–175.
- Rey A** (1964). *L'Examen Clinique en Psychologie*. Presses Universitaires de France: Paris.
- Ricaurte GA, Yuan J, McCann UD** (2000). ($\pm$)-3,4-Methylenedioxymethamphetamine ('ecstasy')-induced serotonin neurotoxicity: studies in animals. *Neuropsychobiology* **42**, 5–10.
- Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott AC** (2003). Patterns of drug use and the influence of gender on self-reports of memory ability in ecstasy users: a web-based study. *Journal of Psychopharmacology* **17**, 389–396.
- Schilt T, de Win MM, Koeter M, Jager G, Korf DJ, van den Brink W, Schmand B** (2007). Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. *Archives of General Psychiatry* **64**, 728–736.
- Schmand B, Bakker D, Saan R, Louman J** (1991). The Dutch Reading Test for Adults: a measure of premorbid intelligence level [in Dutch]. *Tijdschrift voor Gerontologie en Geriatrie* **22**, 15–19.
- Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC** (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of Clinical Psychiatry* **59** (Suppl. 20), 22–33.
- Shepard RN, Metzler J** (1971). Mental rotation of three-dimensional objects. *Science* **171**, 701–703.
- Sinor AD, Irvin SM, Greenberg DA** (2000). Endocannabinoids protect cerebral cortical neurons from *in vitro* ischemia in rats. *Neuroscience Letters* **278**, 157–160.
- Sprague JE, Everman SL, Nichols DE** (1998). An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. *Neurotoxicology* **19**, 427–441.
- Topp L, Barker B, Degenhardt L** (2004). The external validity of results derived from ecstasy users recruited using purposive sampling strategies. *Drug and Alcohol Dependence* **73**, 33–40.
- Van der Elst W, Van Boxtel MP, Van Breukelen GJ, Jolles J** (2005). Rey's verbal learning test: normative data for 1855 healthy participants aged 24–81 years and the influence of age, sex, education, and mode of presentation. *Journal of the International Neuropsychological Society* **11**, 290–302.
- van Ours JC** (2005). Ecstasy and cocaine: patterns of use among prime age individuals in Amsterdam. *Addictive Behaviors* **30**, 1468–1473.
- Wechsler D** (1981). *WAIS-R Manual*. The Psychological Corporation: San Antonio, TX.